Symposium - European Medical Journal

Continue

Symposiums

Hematology
9 Mins
31 Aug 2017

Management of B-Cell Lymphoma: Where Are We Now and Where Are We Going?

The main objectives of the symposium were to explore the current developments in the diagnosis and treatment of non-Hodgkin lymphoma (NHL).
Hematology
9 Mins
8 Aug 2017

Improving Treatment Strategies for Patients with Follicular Lymphoma: How to Translate Novel Study Data into Clinical Practice

Ms Rosmarie Pfau detailed the challenges faced by patients with FL around the world, particularly a desire for improved quality of life (QoL) and…
Hematology
9 Mins
8 Aug 2017

Shifting Treatment Paradigms in Non-Hodgkin Lymphomas

Despite significant therapeutic advances in the treatment of patients with non-Hodgkin lymphoma (NHL), a significant proportion experience relapse or…
Hematology
9 Mins
8 Aug 2017

Biosimilars for Haematologic Malignancies: The Path to Sustainable Care

The main objectives of this symposium were to review the value of biosimilars in sustainable treatment for haematologic malignancies and to recognise the…
Hematology
9 Mins
8 Aug 2017

Patients in Focus: What’s Relevant for Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia?

This symposium was dedicated to discussing BCR-ABL-positive chronic myeloid leukaemia (CML) and Philadelphia-positive acute lymphoblastic leukaemia (Ph+ALL)
Allergy & Immunology
10 Mins
3 Aug 2017

Future of the Allergists and Allergen Specific Immunotherapy (FASIT) Meets EACCI

The FASIT meetings ensure conversations do not remain as just academic discussions in ivory towers, but are shared widely throughout the world
Allergy & Immunology
7 Mins
3 Aug 2017

Controversies on Special Products for Managing Cow’s Milk Protein Allergy in Infants: Safety and Suitability

A Task Force was established with the objective of addressing the need for improved knowledge regarding treatment of infants with CMPA.
Rheumatology
11 Mins
1 Aug 2017

Biosimilars and Switching: What is your Perspective?

The licensing of biosimilars heralds the start of a new era for physicians treating immune and inflammatory diseases.
We’ve noticed you’re accessing
from North/South America.